ACE2 and metabolic syndrome: Changes in protein levels, as detected with the SP-IRIS/ExoView technology, in different RAS components revealed changes similar to those observed for the mRNA cargo (i.e., MetS-induced upregulation of pro-oxidative pro-inflammatory and downregulation of anti-oxidative anti-inflammatory RAS cargo, which was reverted by candesartan treatment), with minor differences possibly related to methodological reasons, such as a candesartan-induced increase in ACE2 protein levels not observed for ACE2 mRNA expression.